NCT01488877View on ClinicalTrials.gov

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Type 2 Diabetic Nephropathy
Interventions
DRUG

PF-03882845

3 mg tablet once daily

DRUG

PF-03882845

up to 10 mg tablet once daily

DRUG

PF-03882845

up to 30 mg once daily

DRUG

Spironolactone

spironolactone 25 mg once daily

OTHER

placebo

placebo once daily

Trial Locations (6)

10019

Pfizer Investigational Site, New York

32720

Pfizer Investigational Site, DeLand

33169

Pfizer Investigational Site, Miami

49007

Pfizer Investigational Site, Kalamazoo

91911

Pfizer Investigational Site, Chula Vista

92123

Pfizer Investigational Site, San Diego

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01488877 - A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy | Biotech Hunter | Biotech Hunter